94 related articles for article (PubMed ID: 1626954)
41. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
[TBL] [Abstract][Full Text] [Related]
42. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
43. [Experiences with the cancer marker CA 125 in gynecologic diseases].
Pilgrim G; von Broen B; Johannsmeyer KD
Z Gesamte Inn Med; 1989 Apr; 44(8):251-4. PubMed ID: 2741520
[TBL] [Abstract][Full Text] [Related]
44. Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma.
Ikeguchi M; Katano K; Saitou H; Tsujitani S; Maeta M; Kaibara N
Hepatogastroenterology; 1997; 44(15):866-71. PubMed ID: 9222706
[TBL] [Abstract][Full Text] [Related]
45. [Chronology of recurrent gastric cancer].
Takahashi Y; Mai M; Ogino T; Ueda H; Ueno M; Kusama S
Nihon Geka Gakkai Zasshi; 1986 Jun; 87(6):604-7. PubMed ID: 2426566
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance of serum P53 antibody in patients with gastric cancer.
Shiota G; Ishida M; Noguchi N; Takano Y; Oyama K; Okubo M; Katayama S; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Ito H; Kawasaki H
Res Commun Mol Pathol Pharmacol; 1998 Jan; 99(1):41-51. PubMed ID: 9523354
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of Ca 12-5 as a tumor marker for gastric and colo-rectal cancer in comparison to CEA and Ca 19-9.
Quentmeier A; Schlag P; Geisen HP; Schmidt-Gayk H
Eur J Surg Oncol; 1987 Jun; 13(3):197-201. PubMed ID: 3474158
[TBL] [Abstract][Full Text] [Related]
48. [Immunocytologic detection of micro-metastatic cells in patients with gastrointestinal tumors].
Juhl H; Kalthoff H; Krüger U; Henne-Bruns D; Kremer B
Zentralbl Chir; 1995; 120(2):116-22. PubMed ID: 7709662
[TBL] [Abstract][Full Text] [Related]
49. [The changes in tumor markers such as serum CEA, CA 19-9, TPA and CA 125 in the chemotherapy of patients with advanced gastric cancer].
Imamura Y; Yasutake K; Yoshimura Y; Oya M; Matsushita K; Tokisue M; Ohno S; Masuda T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1501-7. PubMed ID: 2143888
[TBL] [Abstract][Full Text] [Related]
50. Phospholipids, tumour marker and beta-CrossLaps in diagnosis of gastric carcinoma.
Oremek GM; Sapoutzis N; Lorenz M
Anticancer Res; 2003; 23(2A):859-63. PubMed ID: 12820314
[TBL] [Abstract][Full Text] [Related]
51. [Serum CA125 in gastric cancer patients with peritoneal dissemination].
Ueno M; Takahashi Y; Mai M
Nihon Geka Gakkai Zasshi; 1987 Oct; 88(10):1514. PubMed ID: 3480421
[No Abstract] [Full Text] [Related]
52. [CT and MR diagnosis of metastatic lesions in patients with gastric cancer].
Nakajima H; Ichikawa T; Araki T
Nihon Rinsho; 2001 Apr; 59 Suppl 4():193-8. PubMed ID: 11424376
[No Abstract] [Full Text] [Related]
53. [Evaluation of sialylated LewisX as a tumor-associated carbohydrate antigen in the sera of patients with gastric cancer].
Nakagoe T; Hirota M; Hiratani K; Fukushima K; Shimoyama T; Miura T; Tomita M; Hara K; Ifuku M
Gan No Rinsho; 1989 Mar; 35(4):455-61. PubMed ID: 2565987
[TBL] [Abstract][Full Text] [Related]
54. [The growth rate as a parameter of degree of biological malignancy and prediction of metastasis by tumor marker doubling and half time].
Takahashi Y; Mai M; Kasama S
Nihon Geka Gakkai Zasshi; 1991 Sep; 92(9):1074-7. PubMed ID: 1944157
[TBL] [Abstract][Full Text] [Related]
55. [Treatment of postoperative recurrence of digestive cancers: peritonitis carcinomatosa].
Yamaguchi T; Takahashi T; Sawai K; Hagiwara A; Taniguchi H; Kitamura K; Otsuji E; Sakakura C; Shirasu M; Okamoto K; Yamagishi H
Nihon Geka Gakkai Zasshi; 1999 Feb; 100(2):211-5. PubMed ID: 10331221
[TBL] [Abstract][Full Text] [Related]
56. Carbohydrate antigen 19-9 in tissues and sera from patients with gastric cancer.
Maeta M; Yoshioka H; Shimizu T; Murakami A; Hamazoe R; Koga S
Oncology; 1990; 47(3):229-33. PubMed ID: 2342765
[TBL] [Abstract][Full Text] [Related]
57. Correlation between metastatic site, histological type, and serum tumor markers of gastric carcinoma.
Mori M; Sakaguchi H; Akazawa K; Tsuneyoshi M; Sueishi K; Sugimachi K
Hum Pathol; 1995 May; 26(5):504-8. PubMed ID: 7750934
[TBL] [Abstract][Full Text] [Related]
58. An abnormal elevation of serum CA72-4 by ganoderma lucidum spore powder.
Liang Y; He M; Fan X; Ye W; Yang Z; Zhong R
Ann Clin Lab Sci; 2013; 43(3):337-40. PubMed ID: 23884232
[TBL] [Abstract][Full Text] [Related]
59. [Overexpression of 14-3-3 in primary gastric cancers and clinical application for the detection of micrometastases in the peritoneal cavity].
Shimomura K; Sakakura C; Fujita Y; Nakanishi M; Hagiwara A; Yamagishi H
Nihon Geka Gakkai Zasshi; 2002 Apr; 103(4):386. PubMed ID: 11993230
[No Abstract] [Full Text] [Related]
60. [Studies on treatment of peritonitis carcinomatosa in gastric cancer by intraperitoneal administration of 198Au colloid].
Saito T; Hanatani Y; Yokoyama I; Arai T; Yamada Y; Yatomi K
Nihon Gan Chiryo Gakkai Shi; 1985 Oct; 20(9):2080-6. PubMed ID: 3005447
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
